NCT07239518Not yet recruiting
A Prospective Evaluation of Early Acupuncture for Immediate Continence Enhancement After Prostatectomy
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
This study is being done to see if early acupuncture treatment can help men control their urination better right after their urinary catheter is removed following prostate cancer surgery (radical prostatectomy). Leaking urine is a very common problem immediately after this surgery, and current treatments often start after the catheter is already out. The researchers in this study believe that starting acupuncture before the catheter is removed might help "pre-activate" the nerves and muscles that control urination. This is a prospective, multi-center, randomized, placebo-controlled study. The study plans to enroll 144 men who have had prostate cancer surgery. Participants will be randomly assigned (like flipping a coin) into two groups: Treatment Group (72 participants): Will receive 3 sessions of real electroacupuncture. Control Group (72 participants): Will receive 3 sessions of sham (placebo/fake) acupuncture. This involves using a special blunt needle that touches the skin but does not go in, and a machine that looks like it is on but provides no electricity. The acupuncture or sham treatment will be given 3 times (on post-operative days 7, 9, and 11). The urinary catheter will be removed for all patients on post-operative day 14. All participants will also receive standard education on pelvic floor muscle exercises. The main thing the researchers will measure (the primary endpoint) is the amount of urine leakage (in grams) during a 1-hour pad test, which will be done within the first week after the catheter is removed. Researchers will also check urinary control using questionnaires and other pad tests at 4, 8, 12, and 24 weeks.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 15 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Aug 2027
- Lead sponsor
- Bin Xu
- Diseases
- Prostate cancer
- NCT number
- NCT07239518
What you commit to
- Study type: Interventional
- Planned participants: 144
- From Dec 2025 to the primary completion date, Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pathological results show positive surgical margins.
- Previous treatment for post-operative urinary incontinence, such as cystostomy, urethral sphincter reconstruction, or urethral suspension.
- Currently or within the last 6 months receiving treatment with principles similar to acupuncture (e.g., electroacupuncture, moxibustion, warm moxibustion).
Other illness
- Active urinary system infection (excluding asymptomatic lower urinary tract infection).
- Known severe heart diseases, such as severe arrhythmia, severe heart failure, acute myocarditis, constrictive pericarditis, pericardial tamponade, severe valvular disease, or heart failure.
- Known dysfunction of other vital organs or severe primary diseases, such as hematopoietic system diseases.
- Patients with mental illness or cognitive impairment; patients with severe depression, alcohol dependence, or a history of drug abuse.
Lab values
- Known liver damage or potential severe liver disease (ALT or AST \> 10 times the normal limit).
- Known severe renal impairment (eGFR \< 25mL/min/1.73m2), planned or ongoing dialysis, or acute contrast-induced nephropathy at screening.
- Known coagulation dysfunction (with typical clinical diagnosis or clear laboratory test results).
Other
- Urinary incontinence known to be due to other reasons.
- According to the investigator's judgment, the patient is not suitable for this study or has a high probability of dropout (e.g., frequent changes in work environment that make follow-up difficult).
- Life expectancy ≤ 6 months, as judged by the investigator.
- Currently participating in other clinical trials.
Who the study is looking for
- Patients who have undergone radical prostatectomy with a confirmed pathological diagnosis of prostate cancer.
- One week post-radical prostatectomy (RP).
- Karnofsky Performance Score (KPS) ≥ 60 or ECOG Performance Status 0-1.
- Age between 50 and 85 years.
- Signed informed consent.
Age in the registry: 50 years to 85 years · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.